ArticleJCO precision oncology2022

Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.

Petra Pokorna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.